The Impact of Normal Range of Serum Phosphorus on the Incidence of End-Stage Renal Disease by A Propensity Score Analysis
Authors:
Open Access
- 28 April 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (4) , e0154469
Abstract
Although hyperphosphatemia is deemed a risk factor of the progression of chronic kidney disease (CKD), it remains unclear whether the normal range of serum phosphorus likewise deteriorates CKD. A propensity score analysis was applied to examine the causal effect of the normal range of serum phosphorus on the incidence of end-stage renal disease (ESRD). A retrospective CKD cohort of 803 participants in a single institution was analyzed. Propensity score was estimated using 22 baseline covariates by multivariate binary logistic regression for the different thresholds of time-averaged phosphorus (TA-P) in the normal range of serum phosphorus incremented by 0.1 mg/dL from 3.3 to 4.5 mg/dL. The incidence rate of ESRD was 33.9 per 1,000 person-years over median follow-up of 4.3 years. Total patients showed the mean baseline phosphorus of 3.37 mg/dL and were divided to quartile. The higher quartile was associated with the parameters consistent with the advancement of CKD. A stratified Cox regression showed the highest hazard ratio (HR) at TA-P 3.4 mg/dL (HR 17.60, 95% CI 3.92–78.98) adjusted for baseline covariates such as sex, age, diabetic nephropathy, estimated GFR, serum albumin, Na-Cl, phosphorus, LDL-C and proteinuria. Adjusted HRs remained high up to TA-P 4.2 mg/dL (HR 2.22, 95% CI 1.33–3.71). After propensity score matching conducted at the thresholds of TA-P 3.4, 3.6, 3.8 and 4.0 mg/dL, the higher levels of TA-P showed the higher HRs by Kaplan-Meier analysis (p < 0.05 by stratified log-rank test). The numbers needed to treat were calculated as 3.9 to 5.3 over 5 years. The propensity score analysis shows that even the normal range of serum phosphorus clearly accelerates CKD progression to ESRD. Our results encourage clinicians to target serum phosphorus to inhibit CKD progression in the manner of ‘the lower the better.’Keywords
This publication has 38 references indexed in Scilit:
- Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE InhibitionJournal of the American Society of Nephrology, 2011
- Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control studyBMC Nephrology, 2011
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Diagnosing and responding to violations in the positivity assumptionStatistical Methods in Medical Research, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003Statistics in Medicine, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983